New anticancer agents in clinical development

J. Eckardt, S Gail Eckhardt, M. Villalona-Calero, R. Drengler, D. Von Hoff

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

Original languageEnglish (US)
Pages (from-to)1321-1331
Number of pages11
JournalONCOLOGY
Volume9
Issue number12
StatePublished - Dec 1 1995

Fingerprint

irinotecan
9-aminocamptothecin
docetaxel
gemcitabine
Topoisomerase I Inhibitors
Topotecan
Antimetabolites
Camptothecin
Thymidylate Synthase
Angiogenesis Inhibitors
Cytarabine
Prodrugs
Paclitaxel
Fluorouracil
Genetic Therapy
Biochemistry
Antineoplastic Agents
Signal Transduction
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Eckardt, J., Eckhardt, S. G., Villalona-Calero, M., Drengler, R., & Von Hoff, D. (1995). New anticancer agents in clinical development. ONCOLOGY, 9(12), 1321-1331.

New anticancer agents in clinical development. / Eckardt, J.; Eckhardt, S Gail; Villalona-Calero, M.; Drengler, R.; Von Hoff, D.

In: ONCOLOGY, Vol. 9, No. 12, 01.12.1995, p. 1321-1331.

Research output: Contribution to journalReview article

Eckardt, J, Eckhardt, SG, Villalona-Calero, M, Drengler, R & Von Hoff, D 1995, 'New anticancer agents in clinical development', ONCOLOGY, vol. 9, no. 12, pp. 1321-1331.
Eckardt J, Eckhardt SG, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. ONCOLOGY. 1995 Dec 1;9(12):1321-1331.
Eckardt, J. ; Eckhardt, S Gail ; Villalona-Calero, M. ; Drengler, R. ; Von Hoff, D. / New anticancer agents in clinical development. In: ONCOLOGY. 1995 ; Vol. 9, No. 12. pp. 1321-1331.
@article{d2c67b0dfccf49d5ab9800fc4c989621,
title = "New anticancer agents in clinical development",
abstract = "A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.",
author = "J. Eckardt and Eckhardt, {S Gail} and M. Villalona-Calero and R. Drengler and {Von Hoff}, D.",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "1321--1331",
journal = "Oncology (Williston Park, N.Y.)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

TY - JOUR

T1 - New anticancer agents in clinical development

AU - Eckardt, J.

AU - Eckhardt, S Gail

AU - Villalona-Calero, M.

AU - Drengler, R.

AU - Von Hoff, D.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

AB - A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029554396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029554396&partnerID=8YFLogxK

M3 - Review article

C2 - 8771106

AN - SCOPUS:0029554396

VL - 9

SP - 1321

EP - 1331

JO - Oncology (Williston Park, N.Y.)

JF - Oncology (Williston Park, N.Y.)

SN - 0890-9091

IS - 12

ER -